



May 19, 2026

**National Stock Exchange of India Limited,**  
Compliance Department,  
Exchange Plaza, Bandra Kurla Complex,  
Bandra (East), Mumbai - 400051,  
Maharashtra, India

**BSE Limited,**  
Compliance Department,  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Mumbai - 400001,  
Maharashtra, India

Dear Sir/Madam,

**Subject :** *Intimation regarding the execution of Share Purchase Agreement for the divestment by HealthCare Global Enterprises Limited of its entire equity shareholding in BACC Health Care Private Limited to Inviga Healthcare Fund I*

**Stock Code :** *BSE – 539787, NSE – HCG*

**Reference :** *Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“LODR Regulations”), read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 issued on July 11, 2023, and last updated on January 30, 2026 (“SEBI Circular”)*

In furtherance of our intimation dated May 19, 2026, we would like to inform you that HealthCare Global Enterprises Limited (“the Company”) has entered into a Share Purchase Agreement (“SPA”) dated May 19, 2026, with BACC Health Care Private Limited (“BACC”) and Inviga Healthcare Fund I (“Buyer”) in relation to the divestment by way of sale of the Company’s entire equity shareholding in BACC to the Buyer and its nominee, for a consideration of INR 37,64,44,788 (Indian Rupees Thirty Seven Crores Sixty Four Lakhs Forty Four Thousand Seven Hundred and Eighty Eight Only), on the terms agreed under the SPA. BACC is not a material subsidiary of the Company and is engaged in the business of fertility and reproductive healthcare services, which is not a core business activity of the Company. The said transaction has been approved by the Board and Audit Committee pursuant to the meetings held on May 19, 2026, as disclosed by our intimation dated May 19, 2026.

Please refer to **Annexure - A** for more details in relation to the SPA. The additional disclosures as required under Regulation 30 of the LODR Regulations read with the SEBI Circular are enclosed as **Annexure A**.

The above information is also available on the website of the Company and can be accessed at: <https://www.hcgoncology.com/>

You are requested to take the information on record.

Thanking You,

For HealthCare Global Enterprises Limited

**Sunu Manuel**  
Company Secretary and Compliance Officer.  
Encl: a/a

**HealthCare Global Enterprises Limited**

Reg Off: HCG Towers #8, P. Kalinga Rao Road, Sampangi Ram Nagar, Bengaluru - 560 027, Karnataka, India  
Corp Off: #3, G-Floor, Tower Block, Unity Buildings Complex, Mission Road, Bengaluru - 560 027, Karnataka, India  
91 80 4660 7700 | Email-query@hcgel.com | Website - www.hcgoncology.com | CIN: L15200KA1998PLC023489

Ahmedabad | Bengaluru | Bhavnagar | Chennai | Cuttack | Hubballi | Indore | Jaipur | Kalaburagi | Kenya | Kolkata | Mumbai | Nagpur | Nashik | Ongole | Rajkot | Ranchi | Shimoga | Vadodara | Vijayawada | Vizag



ANNEXURE – A

**Disclosures under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Para 1.4 of Part A of Annexure 18 of the SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 issued on July 11, 2023, and last updated on January 30, 2026.**

Sr. No.	Particulars	Details									
1.	The amount and percentage of the turnover or revenue or income and net worth contributed by such unit or division or undertaking or subsidiary or associate company of the listed entity during the last financial year.	<p>Revenue from operations and net worth of BACC Health Care Private Limited (“BACC”) during the financial year 2025-26:</p> <table border="1"> <thead> <tr> <th>Particulars</th> <th>Amount (INR; in Crores)</th> <th>Percentage of BACC’s revenue and net worth as a % of HCG Standalone revenue from operations and net worth respectively, for the period/year ended March 31, 2026</th> </tr> </thead> <tbody> <tr> <td>Revenue From Operations of BACC for FY 25-26</td> <td>60.45</td> <td>4.45%</td> </tr> <tr> <td>Net worth of BACC as at March 31, 2026</td> <td>17.53</td> <td>1.09%</td> </tr> </tbody> </table> <p>Above figures and percentage are based on the financial statements of BACC and HCG standalone for FY 2025-26</p> <p>Net worth shall mean Total Assets minus Total Liabilities</p>	Particulars	Amount (INR; in Crores)	Percentage of BACC’s revenue and net worth as a % of HCG Standalone revenue from operations and net worth respectively, for the period/year ended March 31, 2026	Revenue From Operations of BACC for FY 25-26	60.45	4.45%	Net worth of BACC as at March 31, 2026	17.53	1.09%
Particulars	Amount (INR; in Crores)	Percentage of BACC’s revenue and net worth as a % of HCG Standalone revenue from operations and net worth respectively, for the period/year ended March 31, 2026									
Revenue From Operations of BACC for FY 25-26	60.45	4.45%									
Net worth of BACC as at March 31, 2026	17.53	1.09%									
2.	Date on which the agreement for sale has been entered into;	The Company has executed the SPA on May 19, 2026.									



3.	The expected date of completion of sale/disposal;	The completion of the Proposed Transaction is expected to occur within 4-5 weeks from the date hereof, subject to the terms of the SPA.
4.	Consideration received from such sale/disposal;	<p>The Company is expected to receive an amount of INR 37,64,44,788 (Indian Rupees Thirty-Seven Crores Sixty-Four Lakhs Forty-Four Thousand Seven Hundred and Eighty-Eight Only) (subject to agreed deductions / adjustments under the SPA), in the following tranches:</p> <p>(a) an aggregate consideration of INR 28,23,33,591 (Indian Rupees Twenty-Eight Crores Twenty-Three Lakhs Thirty-Three Thousand Five Hundred and Ninety-One Only), on the date of closing; and</p> <p>(b) aggregate deferred consideration of INR 9,41,11,197 (Indian Rupees Nine Crores Forty-One Lakhs Eleven Thousand One Hundred and Ninety-Seven Only) within 18 (eighteen) months of the date of signing of the SPA.</p> <p>The deferred consideration referenced above is not a conditional or contingent payment.</p>
5.	Brief details of buyers and whether any of the buyers belong to the promoter/ promoter group/group companies. If yes, details thereof;	<p>The Buyer is Inviga Healthcare Fund I and its nominee.</p> <p>Dr. B.S. Ajaikumar, Promoter and Non-Executive Chairman of the Board of the Company is the Sponsor of the Inviga Healthcare Fund I (“Fund”) and also the Promoter of Inviga Investment Advisors Private Limited, the Investment Manager of the Fund. Accordingly, the Fund is controlled by Dr. B S Ajaikumar.</p>
6.	Whether the transaction would fall within related party transactions? If yes, whether the same is done at “arm’s length”;	<p>Yes, the Proposed Transaction would fall within a related party transaction and is being undertaken on an arm’s length basis.</p> <p>The consideration for the Proposed Transaction was based on, inter alia, a valuation report by an independent third-party valuer.</p> <p>The Company undertook a competitive process in relation to the Proposed Transaction.</p>



7.	Whether the sale, lease or disposal of the undertaking is outside Scheme of Arrangement? If yes, details of the same including compliance with regulation 37A of LODR Regulations.	Not Applicable.
8.	Additionally, in case of a slump sale, indicative disclosures provided for amalgamation/merger, shall be disclosed by the listed entity with respect to such slump sale.	Not Applicable.